
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1214590/publications.pdf Version: 2024-02-01



KAMALA THDIEMED

#	Article	IF	CITATIONS
1	Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. The Lancet Global Health, 2017, 5, e310-e323.	6.3	223
2	Antibiotic Prescribing in DR Congo: A Knowledge, Attitude and Practice Survey among Medical Doctors and Students. PLoS ONE, 2013, 8, e55495.	2.5	144
3	Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends in Parasitology, 2020, 36, 560-570.	3.3	135
4	Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infectious Diseases, The, 2012, 12, 837-844.	9.1	115
5	Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, The, 2019, 394, 929-938.	13.7	106
6	Delayed Parasite Clearance after Treatment with Dihydroartemisinin-Piperaquine in Plasmodium falciparum Malaria Patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 2014, 58, 7049-7055.	3.2	88
7	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	9.1	85
8	Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 2016, 374, 913-927.	27.0	83
9	Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Medicine, 2017, 14, e1002299.	8.4	64
10	Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2019, 19, 91-101.	9.1	56
11	Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal, 2017, 16, 141.	2.3	52
12	The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malaria Journal, 2015, 14, 377.	2.3	51
13	Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE, 2018, 13, e0206331.	2.5	50
14	The Burden of Invasive Bacterial Infections in Pemba, Zanzibar. PLoS ONE, 2012, 7, e30350.	2.5	47
15	Evaluation of a Rapid Dipstick (Crystal VC) for the Diagnosis of Cholera in Zanzibar and a Comparison with Previous Studies. PLoS ONE, 2012, 7, e36930.	2.5	45
16	Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malaria Journal, 2017, 16, 361.	2.3	43
17	Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy. PLoS Neglected Tropical Diseases, 2012, 6, e1743.	3.0	41
18	Supporting evidence for a human reservoir of invasive non-Typhoidal Salmonella from household samples in Burkina Faso. PLoS Neglected Tropical Diseases, 2019, 13, e0007782	3.0	36

#	Article	IF	CITATIONS
19	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
20	A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh. PLoS ONE, 2017, 12, e0169930.	2.5	34
21	Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of Plasmodium vivax in Southern Ethiopia. PLoS ONE, 2015, 10, e0140780.	2.5	33
22	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
23	Population-based incidence, seasonality and serotype distribution of invasive salmonellosis among children in Nanoro, rural Burkina Faso. PLoS ONE, 2017, 12, e0178577.	2.5	31
24	Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003084.	8.4	31
25	Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania. Bulletin of the World Health Organization, 2010, 88, 556-559.	3.3	31
26	A Systematic Review and Meta-Analysis of the Performance of Two Point of Care Typhoid Fever Tests, Tubex TF and Typhidot, in Endemic Countries. PLoS ONE, 2013, 8, e81263.	2.5	29
27	G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS ONE, 2016, 11, e0154015.	2.5	28
28	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
29	Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malaria Journal, 2015, 14, 525.	2.3	26
30	Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure. PLoS Medicine, 2021, 18, e1003494.	8.4	26
31	Clinical and Epidemiological Features of Typhoid Fever in Pemba, Zanzibar: Assessment of the Performance of the WHO Case Definitions. PLoS ONE, 2012, 7, e51823.	2.5	25
32	Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow. Malaria Journal, 2017, 16, 281.	2.3	24
33	Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malaria Journal, 2016, 15, 277.	2.3	21
34	The assessment of gestational age: a comparison of different methods from a malaria pregnancy cohort in sub-Saharan Africa. BMC Pregnancy and Childbirth, 2019, 19, 12.	2.4	21
35	Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet Infectious Diseases, The, 2022, 22, 367-376.	9.1	21
36	THERAPEUTIC EFFICACY OF ARTEMETHER-LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN BANGLADESH. American Journal of Tropical Medicine and Hygiene, 2007, 76, 39-41.	1.4	20

#	Article	IF	CITATIONS
37	Barriers to routine G6PD testing prior to treatment with primaquine. Malaria Journal, 2017, 16, 329.	2.3	19
38	Evidence of a Major Reservoir of Non-Malarial Febrile Diseases in Malaria-Endemic Regions of Bangladesh. American Journal of Tropical Medicine and Hygiene, 2014, 90, 377-382.	1.4	14
39	Health provider experiences with galactagogues to support breastfeeding: a cross-sectional survey. Journal of Multidisciplinary Healthcare, 2016, Volume 9, 623-630.	2.7	14
40	Cost of illness due to typhoid Fever in pemba, zanzibar, East Africa. Journal of Health, Population and Nutrition, 2014, 32, 377-85.	2.0	13
41	Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2007, 76, 39-41.	1.4	13
42	Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria: a multicentre randomized control trial. Reproductive Health, 2015, 12, 5.	3.1	12
43	Utilization and Accessibility of Healthcare on Pemba Island, Tanzania: Implications for Health Outcomes and Disease Surveillance for Typhoid Fever. American Journal of Tropical Medicine and Hygiene, 2013, 88, 144-152.	1.4	11
44	Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and case–control data from Bangladesh. PLoS Medicine, 2021, 18, e1003576.	8.4	10
45	The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008838.	3.0	10
46	Four artemisinin-based treatments in African pregnant women with malaria. Malawi Medical Journal, 2016, 28, 139-149.	0.6	9
47	Analysis of erroneous data entries in paper based and electronic data collection. BMC Research Notes, 2019, 12, 537.	1.4	8
48	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. PLoS Neglected Tropical Diseases, 2020, 14, e0008697.	3.0	8
49	Case Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. American Journal of Tropical Medicine and Hygiene, 2020, 102, 156-158.	1.4	8
50	Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria. PLoS Neglected Tropical Diseases, 2022, 16, e0010406.	3.0	8
51	Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia. Malaria Journal, 2019, 18, 111.	2.3	7
52	Provider and household costs of <i>Plasmodium vivax</i> malaria episodes: a multicountry comparative analysis of primary trial data. Bulletin of the World Health Organization, 2019, 97, 828-836.	3.3	7
53	Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries. Malaria Journal, 2021, 20, 428.	2.3	7
54	Therapeutic efficacy of quinine plus sulfadoxine-pyremethamine for the treatment of uncomplicated falciparum malaria in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2006, 75, 645-9.	1.4	6

0

#	Article	IF	CITATIONS
55	Low risk of recurrence following artesunate–Sulphadoxine–pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. Malaria Journal, 2018, 17, 117.	2.3	5
56	Precarity at the Margins of Malaria Control in the Chittagong Hill Tracts in Bangladesh: A Mixed-Methods Study. Pathogens, 2020, 9, 840.	2.8	5
57	Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned. Malaria Journal, 2020, 19, 205.	2.3	2
58	Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting. Asia and the Pacific Policy Studies, 2021, 8, 208-242.	1.5	2
59	Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA). Trials, 2022, 23, 416.	1.6	2
60	Primaquine for Plasmodium vivax malaria treatment – Authors' reply. Lancet, The, 2020, 395, 1972.	13.7	0
61	Title is missing!. , 2020, 17, e1003084.		0
62	Title is missing!. , 2020, 17, e1003084.		0
63	Title is missing!. , 2020, 17, e1003084.		0
64	Title is missing!. , 2020, 17, e1003084.		0
65	Title is missing!. , 2020, 17, e1003084.		0
66	Title is missing!. , 2020, 17, e1003393.		0
67	Title is missing!. , 2020, 17, e1003393.		0
68	Title is missing!. , 2020, 17, e1003393.		0
69	Title is missing!. , 2020, 17, e1003393.		0

70 Title is missing!. , 2020, 17, e1003393.